SLP Simulations Plus: Company Value to Revenue Ratio

Simulations Plus (SLP) - corporate logo

Geopolitical fragmentation is driving the search for autonomous IT tools for drug development, despite sanction restrictions. The cloud-based biomodeling environment of Simulations Plus, Inc. (SLP) is deeply integrated into R&D processes, creating strong customer dependency. High FDA standards make switching software critically risky for pharma behemoths. The Enterprise Value to Sales ratio demonstrates the business valuation dynamics, where the 3955.28 level serves as a key benchmark.

SLP Simulations Plus Inc.: Company Value to Revenue in the range 11/23/2025 - 10/18/2026

SLP (Simulations Plus Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
Fundamental valuation:SLP - simulations-plus.com
Brand item of Simulations Plus Inc

This indicator compares the total enterprise value of the business with its annual revenue, excluding the impact of leverage. By analyzing the EV/Revenue multiple, an investor determines the fair value of assets during periods of market volatility. A downward trend on this chart signals undervaluation, although it requires a verification of the issuer's solvency. For Simulations Plus, Inc. (SLP), the absence of debt makes this metric exceptionally transparent. The high margins of biosimulation software confirm the fundamental stability of the business.

Competitor analysis

Enterprise Value-to-Revenue Multiple veeva.com|DOCS (Doximity) - Company Value to Revenue|HQY - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Waystar Inc.|CRVL: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Privia Health Group (PRVA)|EV/Sales Multiple huronconsultinggroup.com (HURN)|Certara Inc - Company Value to Revenue|OMCL - Company Value to Revenue|GDRX - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Schrodinger Corp SDGR|PHR: EV/Sales Multiple|OMDA - Total Company Value-to-Revenue Ratio|EVH (Evolent Health Inc) - EV/Sales Multiple|Company Value to Revenue Ratio HSTM (HealthStream)|EV/Sales Multiple DH|CCSI (Consensus Corp) - Business Value to Revenue|agilon health Inc - Company Value to Revenue|absci.com - Enterprise Value-to-Revenue Ratio|SY - Enterprise Value-to-Revenue Ratio|Business Value to Revenue NRC (National Research)|USA Mobility (SPOK) - Enterprise Value-to-Revenue Ratio|OPRX: Enterprise Value-to-Revenue Coefficient|Company Value to Revenue TBRG|Enterprise Value-to-Revenue Multiple sophiagenetics.com SOPH|EV/Sales Multiple HCAT|CCLD (CareCloud Inc.) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Research Solutions Inc. RSSS|DLHC - Company Value to Revenue|ONMD - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Scienture Holdings Inc SCNX|HCTI: EV/Sales Multiple|Company Value to Revenue Ratio ISPC|BFRG (Bullfrog AI) - EV/Sales Multiple|Company Value to Revenue SCWorx Inc (WORX)|EV/Sales Multiple MSPR|ICCT - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple MEDS (TRxADE Health Corp)|Enterprise Value-to-Sales Ratio Orgenesis|R1 RCM - EV/Sales Multiple|Business Value to Revenue SHCR (Sharecare, Inc)|STRM (Streamline Health Solutions Inc.) - Company Value to Revenue|Enterprise Value-to-Revenue Multiple syrahealth.com (SYRA)|Company Value to Revenue AMEH|MODN: Business Value to Revenue|Company Value to Revenue NXGN (NextGen Healthcare)